Translational models of addiction phenotypes to advance addiction pharmacotherapy

被引:4
|
作者
Ray, Lara A. [1 ,2 ,3 ,4 ]
Nieto, Steven J. [1 ]
Grodin, Erica N. [1 ]
机构
[1] Univ Calif Los Angeles, Dept Psychol, 1285 Franz Hall,Box 951563, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Shirley & Stefan Hatos Ctr Neuropharmacol, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA
关键词
addiction; neuroscience; pharmacotherapy; translation; treatment; ALCOHOL DEPENDENCE; PREDICTION ERROR; NEUROCLINICAL ASSESSMENT; SUBJECTIVE RESPONSE; DRUG-ADDICTION; INCENTIVE-SENSITIZATION; NEGATIVE EMOTIONALITY; BEHAVIORAL ECONOMICS; CONSTRUCT-VALIDITY; TREATMENT-SEEKING;
D O I
10.1111/nyas.14929
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Alcohol and substance use disorders are heterogeneous conditions with limited effective treatment options. While there have been prior attempts to classify addiction subtypes, they have not been translated into clinical practice. In an effort to better understand heterogeneity in psychiatric disorders, the National Institute for Mental Health Research Domain Criteria (RDoC) has challenged scientists to think beyond diagnostic symptoms and to consider the underlying features of psychopathology from a neuroscience-based framework. The field of addiction has grappled with this approach by considering several key constructs with the potential to capture RDoC domains. This critical review will focus on the efforts to apply translational models of addiction phenomenology in human clinical samples, including their relative strengths and weaknesses. Opportunities for forward and reverse translation are also discussed. Deep behavioral phenotyping using neuroscience-informed batteries shows promise for a better understanding of the clinical neuroscience of addiction and advancing precision medicine for alcohol and substance use disorders.
引用
收藏
页码:118 / 128
页数:11
相关论文
共 50 条
  • [41] Addiction is Addiction is Addiction
    Schneider, Jennifer P.
    SEXUAL ADDICTION & COMPULSIVITY-THE JOURNAL OF TREATMENT AND PREVENTION, 2005, 12 (2-3): : 75 - 77
  • [42] Pharmacotherapy for addiction and co-morbidity (illicit drugs)
    Tolan, Patrick
    Jurd, Stephen
    Lubman, Dan
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2008, 42 : A46 - A46
  • [43] Introduction to Special Issue "Addiction Pharmacotherapy and Special Populations"
    McCance-Katz, EF
    SUBSTANCE USE & MISUSE, 2005, 40 (13-14) : 1895 - 1897
  • [44] Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction
    Roberts, DCS
    PHYSIOLOGY & BEHAVIOR, 2005, 86 (1-2) : 18 - 20
  • [45] Addiction pharmacotherapy 2000: New options, new challenges
    Rawson, RA
    McCann, MJ
    Hasson, AJ
    Ling, W
    JOURNAL OF PSYCHOACTIVE DRUGS, 2000, 32 (04) : 371 - 378
  • [46] IMPORTANCE OF OXYTOCIN AND DOPAMINE IN ADDICTION: A TRANSLATIONAL APPROACH
    Lee, M. R.
    Tanda, G.
    Rohn, M.
    Yan, J.
    Ramchandani, V. A.
    Schwandt, M. L.
    Newman, A. H.
    Leggio, L.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2015, 39 : 306A - 306A
  • [47] Impact of bidirectional translational research on treatment of addiction
    Kreek, MJ
    CLINICAL NEUROSCIENCE RESEARCH, 2005, 5 (2-4) : 123 - 139
  • [48] Challenges in Translational Research: The Views of Addiction Scientists
    Ostergren, Jenny E.
    Hammer, Rachel R.
    Dingel, Molly J.
    Koenig, Barbara A.
    McCormick, Jennifer B.
    PLOS ONE, 2014, 9 (04):
  • [49] Establishing the feasibility of measuring performance in use of addiction pharmacotherapy
    Thomas, Cindy Parks
    Garnick, Deborah W.
    Horgan, Constance M.
    Miller, Kay
    Harris, Alex H. S.
    Rosen, Melissa M.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2013, 45 (01) : 11 - 18
  • [50] Safety and Early Efficacy of Ibudilast as a Pharmacotherapy for Methamphetamine Addiction
    Shoptaw, Steven
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S105 - S105